Salute e Benessere

Vesper Bio announces successful Phase I study for potentially disease-modifying…

VES001 is a first-in-class oral, brain-penetrant, small molecule sortilin inhibitor rationally designed as a potentially disease-modifying treatment for FTD(GRN). Sortilin is a receptor found on the surface of neurons that competes with progranulin receptors for progranulin binding. Progranulin is degraded when binding to sortilin through an internalization process, leading to further reductions in free progranulin and subsequent neuronal damage and cell death. VES001 is designed to cross the…
PR Newswire
04/09/2024

HKBU develops Chinese medicine for ulcerative colitis approved by National…

Developed based on traditional Chinese medicine formulation Developed based on traditional Chinese medicine formulation Ulcerative colitis, a form of inflammatory bowel disease, is becoming increasingly prevalent. It has a rising morbidity particularly inChinaand other Asian countries. Its main symptoms include diarrhea, rectal bleeding and abdominal cramps, resulting in a reduced quality of life for patients. Ulcerative colitis can be broadly divided into active and remission...
PR Newswire
04/09/2024

Accelerating Circular Fashion: Global Brands and Organisations Inform New…

Over 520 global regulations are currently in place, urging companies to rethink their sourcing and design strategies, emphasising regionalisation and circularity. Moreover 45% of brands surveyed by Global Fashion Agenda and the United Nations Environment Programme earlier this year reported that they have set targets to derive at least 10% of their revenue from circular business models by 2040. However, despite the potential, the fashion industry lacks a comprehensive system for circularity…
PR Newswire
04/09/2024

Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with…

The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD. The results of...
PR Newswire
04/09/2024

Roche's fenebrutinib demonstrated near-complete suppression of disease activity…

New Phase II data show vast majority of patients experiencing no relapses or disability progressionFenebrutinib suppressed acute and chronic MRI lesionsFenebrutinib's safety profile was consistent with previous and ongoing clinical trials across multiple diseases including more than 2,700 people to dateBasel, 04 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new 48-week data for the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib from the...
Nasdaq GlobeNewswire
04/09/2024

Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down…

Press ReleaseNicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board Christine Placet is CFO of Theranexus, and was formerly CEO of Horama and TrophosMichele Garufi, former Chairman and CEO of Nicox, hands over his Board position after over more than 25 years at the company he co-foundedThe Nicox Board has now been entirely renewed to bring in the expertise to support the Company's strategic direction going forwardSeptember 4 ...
Nasdaq GlobeNewswire
04/09/2024

Addex to Participate in the H.C. Wainwright 26th Annual Global Investment…

Geneva, Switzerland, September 4, 2024 - Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending theH.C. Wainwright 26th Annual Global Investment Conferencetaking place September 9 – 11, 2024, at the Lotte New York Palace Hotel. A pre-recorded video presentation by Mr. Dyer in which he provides a...
Nasdaq GlobeNewswire
04/09/2024

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of…

The Issuer's obligations under the notes will be fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals; will rank pari passu in right of payment with the Issuer's existing 2.000% exchangeable senior notes due 2026; will be effectively subordinated to the Issuer's guarantees of the indebtedness under Jazz Pharmaceuticals' credit agreement (the "credit agreement") and Jazz Pharmaceuticals' 4.375% senior secured notes due 2029 (the "senior secured…
PR Newswire
04/09/2024

Deenova announces successful implementation of Closed Loop Medication Management…

Deenova, leading provider of innovative automation solutions for medication management, is proud to announce the successful implementation of its Closed Loop Medication Management (CLMM) system atMarienhospital Gelsenkirchen. This milestone marks the first of its kind in Germany, setting a new standard for medication therapy safety in hospitals nationwide. In partnership with theKERN Katholische Einrichtungen Ruhrgebiet Nord GmbH,Marienhospital Gelsenkirchen (MHG)has begun...
Nasdaq GlobeNewswire
04/09/2024

IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in…

In the first peer-reviewed publication of the IPAX-1 study, Professor Josef Pichler and colleagues report that single or fractionated doses of TLX101 plus EBRT were associated with acceptable tolerability and specific tumour-targeting in patients with recurrent GBM. Authors explain that the study delivered encouraging preliminary efficacy data, demonstrating a median overall survival (OS) of 13 months from the initiation of treatment, or 23 months from initial diagnosis. Given that GBM has a…
PR Newswire
04/09/2024

Global Gastric Cancer Diagnostics Market is Expected to Expand at a CAGR of ~7%…

Key Takeaways from the Gastric Cancer Diagnostics Market Report Key Takeaways from the Gastric Cancer Diagnostics Market Report To read more about the latest highlights related to the gastric cancer diagnostics market, get a snapshot of the key highlights entailed in the Global Gastric Cancer Diagnostics Market Report Gastric Cancer Diagnostics Overview Gastric cancer, or stomach cancer, is typically diagnosed through a combination of clinical evaluation, imaging techniques,...
PR Newswire
03/09/2024

Global Healthcare Testing, Inspection, and Certification Market to Exhibit…

Key Takeaways from the Healthcare Testing, Inspection, and Certification Market Report Key Takeaways from the Healthcare Testing, Inspection, and Certification Market Report To read more about the latest highlights related to the healthcare testing, inspection, and certification market, get a snapshot of the key highlights entailed in the Global Healthcare Testing, Inspection, and Certification Market Report Healthcare Testing, Inspection, and Certification Overview Healthcare...
PR Newswire
03/09/2024

QIAGEN N.V. announces conversion price of new net share settled convertible…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN " or the " Company ") announces the final terms of the new senior, unsecured net share settled convertible bonds, which may be converted, in part, into…
Nasdaq GlobeNewswire
03/09/2024

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing…

Globally, breast cancer continues to be the most prevalent malignancy in women. Among all subtypes, triple-negative breast cancer (TNBC) stands out as the most aggressive form with high metastatic potential and poor survival rates.Despite a few emerging targeted therapies under investigation, surgery, chemotherapy and radiation therapy continue to be the standard of care, and their success remains limited. As an alternative, Chimeric Antigen Receptor (CAR) T-cell therapies could hold...
Nasdaq GlobeNewswire
03/09/2024

Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment…

PARIS and CAMBRIDGE, Mass., Sept.03, 2024(GLOBE NEWSWIRE) -- NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming H.C. Wainwright 26 thAnnual Global Investment conference. Please see below for details of the event. H.C. Wainwright 26 th...
Nasdaq GlobeNewswire
03/09/2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08.The Company is issuing this...
Nasdaq GlobeNewswire
03/09/2024

Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium; 3 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation 1, Galapagos received a transparency notification on 30 August 2024 from FMR LLC, who notified that it holds 2,687,116 of Galapagos' voting rights, consisting of 2,686,016 ordinary shares and 1,100 equivalent financial instruments. FMR LLC controls investment funds Fidelity...
Nasdaq GlobeNewswire
03/09/2024

Innocan Pharma Advances Liposomal CBD with Positive Response from FDA Following…

In addition, Innocan has reached an alignment with the FDA on both its non-clinical development plan and the clinical study design for LPT-CBD's proposed Investigational New Drug (IND) filing for a Phase I clinical study. In addition, Innocan has reached an alignment with the FDA on both its non-clinical development plan and the clinical study design for LPT-CBD's proposed Investigational New Drug (IND) filing for a Phase I clinical study. Professor Chezy Barenholz, Innocan's Chief...
PR Newswire
03/09/2024

Frost Radar™ Positions 14 Top Growth & Innovation Leaders in Global Healthcare…

Frost & Sullivan has meticulously vetted over 80 healthcare data interoperability vendors, identifying the leading 14 companies poised to revolutionise the industry with their rapid corporate growth and visionary innovation. These companies are recognised for their strong presence across multiple segments and their capacity to enhance data management and orchestration by facilitating seamless data exchange among internal and external sources. Frost & Sullivan has meticulously vetted over…
PR Newswire
03/09/2024

QIAGEN N.V. announces successful placement of new net share settled convertible…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE. QIAGEN ") announces certain terms of the new senior, unsecured net share settled convertible bonds, which may be converted, in part, into ordinary shares of QIAGEN…
Nasdaq GlobeNewswire
03/09/2024

Proteomics Market worth $60.5 billion by 2029 driven by Rising Tech Innovations…

Browse in-depth TOC on "Proteomics Market" Browse in-depth TOC on "Proteomics Market" 707 - Tables49 - Figures578 - Pages Thermo Fisher Scientific, Inc.: Leading Innovation in Proteomics Thermo Fisher Scientific, Inc. (US) holds a dominant position in the proteomics market due to its diverse product portfolio, global presence, and strategic growth initiatives. The company employs both organic and inorganic strategies, including partnerships and acquisitions, to...
PR Newswire
03/09/2024

HeiQ advances synbiotic cleaning as a sustainable solution to antimicrobial…

HeiQ's synbiotic cleaning technology, combining probiotics (good bacteria) with prebiotics (food for good bacteria) has been scientifically proven to be an efficient solution to improve cleanliness in general institutions, healthcare facilities, farms, and industry. Recent scientific studies at hospitals in Germany and Italy[1] have shown a significant decrease in antimicrobial resistance genes and a strong reduction in the need for disinfectants and antibiotics. HeiQ's synbiotic cleaning...
PR Newswire
03/09/2024

Coloplast A/S - Trading in Coloplast shares by board members, executives or…

Please see enclosed pdf. Attachment 03092024_trading_in_shares_ASL
Nasdaq GlobeNewswire
03/09/2024

UPPAbaby Unveils New Strollers at Kind + Jugend, Enhancing Every Journey of…

Just when the industry and customers thought UPPAbaby had delivered its most significant innovation with the globally acclaimed Vista V3 stroller last May, the brand once again surprises and delights by unveiling the Minu V3 and Minu Duo at Kind + Jugend. These strollers are not just about innovation; they reflect UPPAbaby's deep understanding of parenthood and the challenges that come with it, especially when traveling. Just when the industry and customers thought UPPAbaby had delivered…
PR Newswire
03/09/2024
Altri  Comunicati